Lipoproteins and the endothelium: Insights from clinical research

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 5, 2000, Pages 513-519

  Dugi, K A ^a   Rader, D J ^a  

^a Dept Int Med I ^*  (Germany)

Author keywords

Atherothrombotic disease; Endothelial dysfunction; Hyperlipidemia; Statins; Treatment

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CORONARY RISK; HUMAN; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 0033636078     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13207     Document Type: Review

References (78)

1. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
2. Prevalence of risk factors in men with premature coronary artery disease
3. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
4. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
5. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men
6. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
7. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels
8. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins
9. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects
10. Apolipoprotein A-I containing lipoproteins in coronary artery disease
11. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
12. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
13. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
14. Endothelial function in health and disease: New insights into the genesis of cardiovascular disease
15. Coronary risk factors, endothelial function, and atherosclerosis: A review
16. Special article: Non-invasive measurement of endothelial function
17. Coronary flow reserve is impaired in young men with familial hypercholesterolemia
18. Reduced coronary flow reserve in familial hypercholesterolemia
19. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by 1-arginine
20. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia
21. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension
22. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries
23. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis
24. Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia
25. Altered myocardial vasodilatation in patients with hypertriglyceridemia in anatomically normal coronary arteries
26. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation
27. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries
28. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity
29. Effect of a single high-fat meal on endothelial function in healthy subjects
30. Levels of soluble cell adhesion molecules in patients with dyslipidemia
31. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men
32. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis
33. Hypertriglyceridaemia and hypercoagulability
34. Activation of coagulation factor VII during alimentary lipemia
35. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease
36. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
37. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
38. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
39. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma
40. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias
41. Platelet function in hyperlipoproteinemia
42. Platelet-dependent thrombin generation in patients with hyperlipidemia
43. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome
44. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene
45. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
46. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
47. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
48. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
49. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
50. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
51. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
52. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis
53. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
54. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate
55. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
56. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
57. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
58. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
59. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men
60. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris
61. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
62. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis
63. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse
64. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
65. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium
66. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
67. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
68. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
69. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults
70. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
71. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study
72. Upregulation of endothelial nitric oxide Synthase by HMG CoA reductase inhibitors
73. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia
74. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia
75. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
76. Effect of atorvastatin on plasma fibrinogen
77. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
78. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction